Vaxcyte’s stock jumps as pneumococcal vaccine holds its own against Pfizer's, Merck’s shots
Vaxcyte’s stock jumps as pneumococcal vaccine holds its own against Pfizer's, Merck’s shots Fierce Biotech
Covered in this story
Analyst targets on Pfizer
- HSBC: $23.7 → $28 by Jul 2027 · Hold via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $PFE yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Pfizer →Dalsna Finance is currently tracking 49 stories mentioning Pfizer, the earliest published 22 May 2026.
Summary aggregated from Fierce Biotech's public RSS feed. The full reporting belongs to Fierce Biotech — please read it on their site.